Title: Papillary muscle free strain- promising parameter to predict
sudden cardiac death in hypertrophic cardiomyopathy?
Author:
Dr Aslannif Roslan (MBBS, MRCP)
Institut Jantung Negara,
50400 Kuala Lumpur,
Malaysia
E-mail: Elysess1@gmail.com
Corresponding author:
Dr Aslannif Roslan (MBBS, MRCP)
Institut Jantung Negara,
50400 Kuala Lumpur,
Malaysia
E-mail:Elysess1@gmail.com
Hypertrophic Cardiomyopathy (HCM) generally have a good prognosis. In
the long follow-up study over 5 decades annual overall HCM-related
mortality was 1.3%/y (0.7% first decade to 1.8% in second and third
decades). The sudden cardiac death (SCD) mortality rate was also low
(0.1%/y first decade to 0.44% in second and third
decades)1. SCD is the most feared HCM complication and
the only effective treatment for this is Implantable Cardioverter
Defibrillator (ICD) that is responsible for >10-fold decrease
in HCM related mortality2. In 2014,the European
Society of Cardiology (ESC) come out with risk score comprising 7
variables but this risk score have low sensitivity3,4.
This led to the search for additional risk factors such as percentage of
late gadolinium enhancement (LGE) in the left ventricle, presence of
apical aneurysm and left ventricle ejection fraction <50% .The
American Society of Cardiology/American Heart Association (ACC/AHA)
incorporate this for their guidelines in
20205.Eventhough this guidelines have high
sensitivity, it have low ability to identify low risk patients which can
lead to inappropriate ICD implantation4. The ongoing
challenge is to identify the small yet significant group of patients who
are at risk of sudden cardiac death, heart failure, and death resulting
from heart failure.
Neither the 2014 nor the 2020 SCD risk calculators/predictors, nor even
the latest 2022 ESC guidelines, have incorporated the relatively new
echocardiography technique of speckle-tracking strain measurements. This
technique is non-doppler oriented, angle independent and have been shown
to be highly reproducible with high sensitivity and
specificity6. These techniques can measure Global
longitudinal strain (GLS), left atrial reservoir (LArS), conduit (LAcS)
and booster (LAbS) strain and right ventricle global (RVGLS) and free
wall strain (RVFWS). The most studied of these is Global Longitudinal
Strain (GLS) and a recent study showed GLS have the highest accuracy to
predict fatal arrhythmia and accurate ICD indication compare to all the
other echocardiographic parameters that was previously considered
important like diastolic left atrial (LA) diameter, left ventricular
wall thickness and ejection fraction7.This is
consistent with another study of large cohort of 427 HCM patients
showing independent association between GLS and all cause mortality,
heart transplantation, aborted SCD, and appropriate ICD
therapy8. Furthermore, the latest meta-analysis of 13
studies with 2441 HCM patients showed significant correlation between
impaired GLS and major adverse cardiovascular outcomes (MACE). The same
correlation was also found with LA strain. A recent meta-analysis in
2023 shows significant association between all aspect of LA strain
(reservoir, conduit and booster) with MACE as well as development of new
atrial fibrillation (AF)9. This is not only true with
echocardiography derived strain. In a Cardiac MRI (CMR) strain study
published in 2024, the combination of left ventricle circumferential
strain and left atrial reservoir strain model shows high diagnostic
value of SCD with staggeringly high area under the curve (AUC) of
0.9510. All of these studies show how powerful is
strain study in HCM SCD prognosis and it is natural to then look at
papillary muscle (PM) strain as this structure is frequently abnormal in
HCM11.
It is widely known that papillary muscle abnormalities are part of HCM
phenotypes, in addition to elongated mitral valve leaflets and
hypertrophied muscle with excessive contractility (the sine qua non of
HCM)11. Abnormal papillary muscle morphology is
independently associated with increase left ventricular outflow tract
(LVOT) obstruction with anteroapically displaced PM and double bifid PM
patients having higher resting LVOT gradients than control independent
of septal thickness, use of rate control medications and resting heart
rate12. The variations of papillary muscle
abnormalities are anterior and apical displacement of the PM usually
involving ALPM, bifid PM characterized by the presence of more than one
muscle head (If both PM involved it is called double bifid morphology),
accessory PM that extend from the LV apex and inserted to basal
myocardium without insertion into the mitral leaflets and anomalous
insertion of the PM itself12,13,14.In HCM, the PM are
frequently hypertrophied, with a mass measuring roughly twice the
healthy controls. HCM patients also tend to have larger number of PM
(2.5 muscles vs 2.1 in control) with half of the patients demonstrating
multiple (3 or 4) PM15.
In this issue of Echocardiography Atilla Koyuncu et al look at 79
patients with HCM that were divided into low/intermediate-risk (n=57,
ESC risk score <6 points) and high risk (n=22, ESC risk score ≥6
points) groups based on the ESC risk calculator. Their mean follow-up
duration is 6.2 years. They specifically look for PM abnormalities and
measured anterolateral papillary muscle (ALPM) and posteromedial
papillary muscle (PMPM) free strain in addition to other conventional
2-dimensional echocardiographic parameters and GLS. They enrolled all
HCM phenotypic groups with or without obstruction and they exclude
patients with hypertension, valvular heart diseases, hepatic/renal
failure or inflammatory diseases. Of note, they did not perform left
atrium (LA) or right ventricle (RV) strain. Papillary muscle strain is a
relatively new tool and the measurements of ALPM strain is done in
apical 4 chamber view and measurement for PMPM strain is done in apical
3 chamber view. The majority of patients have sigmoid or reverse
curvature phenotype (70.9%). Interestingly 5 patients (6.3%) had
anteriorly displaced papillary muscles, 7(8.8%) had bifid ALPM,
5(6.3%) had bifid PMPM and 2 patients have both bifid ALPM and PMPM
(double bifid morphology).
They found that the high SCD-risk group had greater wall thickness,
interventricular septum thickness, posterior wall thickness and left
ventricle mass index and lower GLS, ALPM (-16.88 ± 4.41% vs. -14.34 ±
3.68%, p = .028) and PMPM (-18.48 ± 6.31% vs. -15.28 ± 6.88%, p =
.042) free strain. Furthermore, the SCD risk score was positively
correlated with GLS, ALPM (r=0.658, p<0.001) and PMPM (r=0.600,
p<0.001) strain. Also important is the fact that patient who
have papillary muscle abnormalities had significantly worse ALPM and
PMPM free strain. Finally, in multivariate analysis, LVMI, presence of
syncope, worse GLS and ALPM-free strain were predictors of death. In
terms of PM free strain value in normal healthy populations, one study
done in 2016 shows between -32.5% to -48% for ALPM and -34.5% to
-39.5% for PMPM but for the moment at least there are no guidelines for
normal values16.
What is the relevance of this paper for our understanding of HCM? It
introduces an additional parameter that is easy to measure and
reproducible alongside GLS and LA strain, aiding in the prediction of
SCD. Although the technique is new and the sample size is limited,
further studies with larger populations are necessary to establish its
predictive value for SCD, similar to GLS. As strain measurements are
generally robust and reproducible, papillary muscle strain has the
potential to replace traditional parameters like left atrial dimension,
wall thickness, and ejection fraction. Moreover, this paper highlights
the importance of considering papillary muscle involvement in HCM,
drawing attention to abnormalities such as bifid papillary muscles and
anterior displacement during strain measurement. Ultimately, by
integrating papillary muscle free strain with GLS, RV, and LA strain, we
can enhance our ability to predict sudden cardiac death and ensure more
appropriate ICD implantation. For clinicians focused on managing HCM,
these are exciting times, and this paper provides valuable insights into
the field.
- Maurizi N, Olivotto I, Maron M, et al. Lifetime clinical course of
hypertrophic cardiomyopathy: Outcome of the historical Florence cohort
over five decades. JACC Adv. 2023;2(4).
doi:10.1016/j.jacadv.2023.100337
- Maron MS, Rowin EJ, Maron BJ. The paradigm of sudden death prevention
in hypertrophic cardiomyopathy. Am J Cardiol. 2024;212S:S64-S76.
doi:10.1016/j.amjcard.2023.10.076
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines
for the management of patients with ventricular arrhythmias and the
prevention of sudden cardiac death. Eur Heart J. 2022;26:ehac262.
doi:10.1093/eurheartj/ehac262
- Monda E, Limongelli G. Integrated sudden cardiac death risk prediction
model for patients with hypertrophic cardiomyopathy. Circulation.
2023;147(4):281-283. doi:10.1161/CIRCULATIONAHA.122.063019
- Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the
diagnosis and treatment of patients with hypertrophic cardiomyopathy:
A report of the American College of Cardiology/American Heart
Association Joint Committee on Clinical Practice Guidelines.
Circulation. 2020;142:e558–e631. doi:10.1161/CIR.0000000000000937
- Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance
of the left ventricular collagen network in young patients with
hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll
Cardiol. 2000;35(1):36-44. doi:10.1016/s0735-1097(99)00492-1
- Nikoo MH, Zarrabi M, Moaref A, Razeghian-Jahromi I. Global
longitudinal strain may be the one that appropriately identifies
candidates for ICD implantation. Cardiol Res Pract. 2024;2024:2214072.
doi:10.1155/2024/2214072
- Hiemstra YL, Debonnaire P, Bootsma M, et al. Global longitudinal
strain and left atrial volume index provide incremental prognostic
value in patients with hypertrophic cardiomyopathy. Circ Cardiovasc
Imaging. 2017;10(7): e005706. doi:10.1161/CIRCIMAGING.116.005706
- Hussain K, Nso N, Tsourdinis G, et al. A systematic review and
meta-analysis of left atrial strain in hypertrophic cardiomyopathy and
its prognostic utility. Curr Probl Cardiol. 2024;49(1 Pt C):102146.
doi:10.1016/j.cpcardiol.2023.102146
- Zhu X, Shi Y, Lian J, et al. Left atrial and left ventricular strain
in feature-tracking cardiac magnetic resonance for predicting patients
at high risk of sudden cardiac death in hypertrophic cardiomyopathy.
Quant Imaging Med Surg. 2024;14(5):3544-3556.
doi:10.21037/qims-23-1615
- Sherrid MV, Adams DH. The mitral valve in hypertrophic cardiomyopathy:
Other side of the outflow tract. J Am Coll Cardiol.
2020;76(19):2248-2251. doi:10.1016/j.jacc.2020.09.580
- Kwon DH, Setser RM, Thamilarasan M, et al. Abnormal papillary muscle
morphology is independently associated with increased left ventricular
outflow tract obstruction in hypertrophic cardiomyopathy. Heart.
2008;94(10):1295-1301. doi:10.1136/hrt.2007.118018
- Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural
mitral valve alterations in hypertrophic cardiomyopathy. Circulation.
1992;85(5):1651-1660. doi:10.1161/01.cir.85.5.1651
- Gruner C, Chan RH, Crean A, et al. Significance of left ventricular
apical-basal muscle bundle identified by cardiovascular magnetic
resonance imaging in patients with hypertrophic cardiomyopathy. Eur
Heart J. 2014;
- Rajiah P, Fulton NL, Bolen M. Magnetic resonance imaging of the
papillary muscles of the left ventricle: Normal anatomy, variants, and
abnormalities. Insights Imaging. 2019;10(1):83.
doi:10.1186/s13244-019-0761-3
- Kılıcgedik A, Kahveci G, Gurbuz AS, et al. Papillary muscle free
strain in patients with severe degenerative and functional mitral
regurgitation. Arq Bras Cardiol. 2017;108(4):339-346.
doi:10.5935/abc.20170035